home / stock / phat / phat news

PHAT News and Press, Phathom Pharmaceuticals Inc. From 10/18/21

Stock Information
Company Name: Phathom Pharmaceuticals Inc.
Stock Symbol: PHAT
Market: NYSE
Website: phathompharma.com
Menu
PHAT PHAT Quote PHAT Short PHAT News PHAT Articles PHAT Message Board
Get PHAT Alerts

News, Short Squeeze, Breakout and More Instantly...
PHAT - Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phases Vonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus lansoprazole (PREVACID ® ), a proton pump inhibitor (PPI) Vonopr...
PHAT - Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)

Vonoprazan 20 mg demonstrated significantly greater acid suppressive effects over the 7-day study period compared to lansoprazole (PREVACID ® ) 30 mg, a proton pump inhibitor (PPI) FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.&#x...

PHAT - Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital

FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 million t...

PHAT - Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has submitted two new drug a...
PHAT - Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, President and CEO...

PHAT - Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones

Pivotal Phase 3 PHALCON-EE trial topline data for vonoprazan in erosive esophagitis expected in October 2021 Phase 2 PHALCON-NERD on-demand trial for vonoprazan in non-erosive reflux disease enrolling ahead of schedule with topline data now expected in the first quarter of 2022 ...

PHAT - Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.

FLORHAM PARK, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the sad news that its chairman and fo...
PHAT - Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI

FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, Phathom’s ...

PHAT - Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

PHAT - Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team wi...
Previous 10 Next 10